Last reviewed · How we verify
NCT05151289: ANGIOPAG
Diagnostic Value of sFlt-1/PlGF Ratio for the Etiology of Intra Uterine Growth Restriction - ANGIOPAG
NA trial testing Blood test at time of inclusion for sFlt-1/PlGF ratio in Intrauterine Growth Restriction in 152 participants. Status unknown.
29 January 2022
Quick facts
| Lead sponsor | Assistance Publique - Hôpitaux de Paris |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 152 |
| Start date | 8 January 2020 |
| Primary completion | 29 January 2022 |
| Estimated completion | 29 January 2022 |
| Sites | 1 location across France |
Drugs / interventions tested
- Blood test at time of inclusion for sFlt-1/PlGF ratio — full drug profile →
- Follow-up blood test 2 to 4 weeks after inclusion — full drug profile →
- Placenta analysis for all included patients, even in case of normal birthweight
Conditions studied
- Intrauterine Growth Restriction — all drugs for Intrauterine Growth Restriction →
- Fetal Growth Restriction (FGR) — all drugs for Fetal Growth Restriction (FGR) →
Sponsor
Assistance Publique - Hôpitaux de Paris — full company profile →
Who can join
18 and older, female only, with Intrauterine Growth Restriction or Fetal Growth Restriction (FGR). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main aim of this project is to determine the Placental Growth Factor and Vascular Endothelial Growth Factor ratio's performance (sFlt-1/PlGF) for the etiological diagnosis of vascular Intrauterine growth restriction (IUGR) compared to a non-vascular IUGR.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05151289
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Intrauterine Growth Restriction
Currently open trials in the same condition.
- NCT06534307 — Long-term Follow-up of Children Born in the PETN Studies · recruiting
- NCT06115122 — PEPPI Study: Identification of Women at Risk for Placental Dysfunction · recruiting
- NCT06074601 — MIRACLE of LIFE Study · active not recruiting
- NCT04766866 — sFlt1/PlGF and Planned Delivery to Prevent Preeclampsia at Term. · NA · recruiting
- NCT03398629 — Diagnosis and Management of Intrauterine Growth Restriction and Congenital Anomalies · recruiting
Other Assistance Publique - Hôpitaux de Paris trials
Trials by the same sponsor.
- NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
- NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
- NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
- NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
- NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05151289 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
- Last refreshed: 9 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05151289.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing